India’s vital API market, currently a $15-16 billion powerhouse, anticipates 5-7% CAGR in the coming fiscal years FY27 and FY28. CareEdge Ratings’ report unpacks the drivers: policy tailwinds, a shift to premium APIs, homegrown demand surge, and global market inroads.
Pharma giants are ditching basic APIs for complex ones to stabilize prices, widen margins, and lock in clientele amid fierce competition.
China’s grip on raw material supplies lingers as a risk, but countermeasures are working. Over 30 PLI-backed projects are done, and new plants are operational. ‘Tangible progress is underway, with broader effects on the horizon,’ the report affirms.
High-potency API pipelines are maturing, eyeing commercialization soon and lifting India’s position in pharmaceutical hierarchies—though peak benefits trail by 2-4 years.
Long-haul growth hinges on aging societies, superior healthcare reach, insurance booms, chronic disease upticks, monopoly erosion, and emerging market pushes, per Pritesh Rathi.
Bulk Drug Parks dominate, fueling 80% of initiatives with mega-investments. Andhra Pradesh, Himachal Pradesh, and Gujarat host 20-40 billion rupee behemoths aimed at production dominance, import reduction, and efficiency gains. This era heralds India’s API sector as a global contender.